Norbert Marschner

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

G. Minckwitz, C. Lévy, A. Fontana, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

F. Lordick, D. Strumberg, R. Hilger, 2012, Investigational New Drugs.

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

R. Souchon, S. Loibl, G. von Minckwitz, 2005, Anti-cancer drugs.

Clinical Epidemiology Dovepress

J. Möttönen, R. Sulkava, E. Leskinen, 2022 .

ABC3 Consensus Commented from the Perspective of the German Guidelines

F. Marmé, N. Harbeck, M. Untch, 2016, Geburtshilfe und Frauenheilkunde.